A Double-Blind, Placebo-Controlled Study of Quetiapine and Paroxetine as Monotherapy in Adults With Bipolar Depression (EMBOLDEN II)
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of quetiapine and paroxetine monotherapy for major depression in bipolar disorder. METHOD: 740 patients (478 bipolar I, 262 bipolar II) with major depressive episodes (DSM-IV) were randomly assigned to quetiapine 300 mg/d (n = 245), quetiapine 600 mg/d (n = 247), paroxetine 20 mg/d (n = 122), or placebo (n = 126) for 8 weeks. The primary end point was the change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The study was conducted from May 2005 to May 2007. RESULTS: Mean MADRS score change from baseline at 8 weeks was -16.19 for quetiapine 300 mg, -16.31 for quetiapine 600 mg, -13.76 for paroxetine, and -12.60 for placebo (P < .001 for both quetiapine doses, P = .313 for paroxetine, vs placebo). Quetiapine-treated (both doses), but not paroxetine-treated, patients showed significantly greater improvements (P < or = .05) in most secondary outcomes measures at week 8 versus the placebo group. Paroxetine significantly improved Hamilton Anxiety Rating Scale scores versus placebo (P < .05) but not MADRS or Hamilton Depression Rating Scale (HDRS) scores. Both quetiapine doses were associated with greater improvements than paroxetine for MADRS and HDRS scores. The most common adverse events were dry mouth, somnolence, sedation, and dizziness with quetiapine (both doses) and dry mouth, sedation, headache, insomnia, and nausea with paroxetine. The incidence of treatment-emergent mania/hypomania was lower with quetiapine compared with paroxetine and placebo. CONCLUSIONS: Quetiapine (300 or 600 mg/d), but not paroxetine, was more effective than placebo for treating acute depressive episodes in bipolar I and II disorder. Quetiapine treatment was generally well tolerated. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00119652.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antidepressants should not be used as monotherapy in patients with BDI depression, as available trials do not support their efficacy and there are concerns about their safety in terms of mood switching (level 2 negative).260, 289, 290, 291”
In the citing paper
“Antidepressants should not be used as monotherapy in patients with BDI depression, as available trials do not support their efficacy and there are concerns about their safety in terms of mood switching (level 2 negative).260, 289, 290, 291”
In the citing paper
“The latter finding must be reconciled with the fact that quetiapine beat placebo in only three of the five individual trials in patients with BDII, compared to all five in patients with BDI.253, 290, 438, 439, 440”
In the citing paper
“Further, secondary analyses from several RCTs indicate that quetiapine monotherapy significantly reduces symptoms of GAD and panic disorder in patients with bipolar depression.290, 313, 725”
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
(1976) · Medical Entomology and Zoology · Cited by 8,899
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
No health without mental health
Prince, M., Patel, V., Saxena, S., Maj, M., Maselko, J., Phillips, M. R., & Rahman, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61238-0 · Cited by 3,753
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Merikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
(1993) · PubMed · Cited by 1,900
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Self-citationJudd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243
Excess Mortality in Bipolar and Unipolar Disorder in Sweden
Ösby, U., Brandt, L., Correia, N., Ekbom, A., & Sparén, P. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.9.844 · Cited by 1,120
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
Spearing, M. K., Post, R. M., Leverich, G. S., Brandt, D., & Nolen, W. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(97)00123-6 · Cited by 978
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064135 · Cited by 937 · cited 2×
“The common practice of employing antidepressants (often as monotherapy) to treat bipolar I and in particular bipolar II depressed patients appears to need reexamination by clinicians in light of this study and the STEP-BD results.(16)”
BackgroundSheehan, D. V. (1984) · Medical Entomology and Zoology · Cited by 883
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 5×
“These findings confirm the acute antidepressant effects of quetiapine that were previously reported in the BOLDER studies, in which significant improvements associated with quetiapine treatment were reported from week 1.(23,24) The fixed doses of quetiapine used in this study were consistent with the BOLDER studies an…”
BackgroundResultInfluentialSelf-citationMortality of patients with mood disorders: follow-up over 34–38 years
Angst, F., Stassen, H. H., Clayton, P. J., & Angst, J. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00377-9 · Cited by 881
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.12.1 · Cited by 583
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Leon, A. C., Solomon, D. A., Coryell, W., Maser, J. D., & Keller, M. B. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.12.1322 · Cited by 577
Antidepressants for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials
Gijsman, H. J., Geddes, J. R., Rendell, J. M., Nolen, W. A., & Goodwin, G. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1537 · Cited by 563
Thase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., & Calabrese, J. R. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248603.76231.b7 · Cited by 559 · cited 5×
“These findings confirm the acute antidepressant effects of quetiapine that were previously reported in the BOLDER studies, in which significant improvements associated with quetiapine treatment were reported from week 1.(23,24) The fixed doses of quetiapine used in this study were consistent with the BOLDER studies an…”
BackgroundResultInfluentialSelf-citationGrant, B. F., Stinson, F. S., Hasin, D. S., Dawson, D. A., Chou, S. P., Ruan, W. J., & Huang, B. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1001 · Cited by 479 · cited 1×
“3%, suggesting that the economic implications of this illness may have been previously underestimated.(4) Screening studies have shown bipolar disorder to be particularly common in primary care practices, where patients usually present with depression.”
BackgroundInduction of Mania with Selective Serotonin Re-uptake Inhibitors and Tricyclic Antidepressants
Peet, M. (1994) · British Journal of Psychiatry · doi:10.1192/bjp.164.4.549 · Cited by 474 · cited 1×
“antidepressants and venlafaxine, and an only slightly higher risk than that associated with bupropion.(17,29)”
BackgroundLeverich, G. S., Altshuler, L. L., Frye, M. A., Suppes, T., McElroy, S. L., Keck, P. E., Kupka, R. W., Denicoff, K. D., Nolen, W. A., Grunze, H., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.232 · Cited by 419 · cited 2×
“antidepressants and venlafaxine, and an only slightly higher risk than that associated with bupropion.(17,29)”
BackgroundResultSelf-citationNemeroff, C. B., Evans, D. L., Gyulai, L., Sachs, G. S., Bowden, C. L., Gergel, I. P., Oakes, R., & Pitts, C. D. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.906 · Cited by 407
Young, A. H., McElroy, S. L., Bauer, M., Philips, N., Chang, W., Olausson, B., Paulsson, B., Brecher, M., & EMBOLDEN I (Trial 001) Investigators (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04995gre · Cited by 390 · cited 2×
“2%).(25) The safety and tolerability profile of quetiapine observed in the current study was generally consistent with that reported in the BOLDER trials.”
MethodResultSelf-citationThe Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity.
Clayton, A. H., McGarvey, E. L., & Clavet, G. J. (1997) · PubMed · Cited by 358
Quality of life in bipolar disorder: A review of the literature
Michalak, E. E., Yatham, L. N., & Lam, R. W. (2005) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-3-72 · Cited by 295
Patterns of Psychotropic Drug Prescription for U.S. Patients With Diagnoses of Bipolar Disorders
Baldessarini, R. J., Leahy, L., Arcona, S., Gause, D., Zhang, W., & Hennen, J. (2007) · Psychiatric Services · doi:10.1176/ps.2007.58.1.85 · Cited by 280 · cited 1×
“with bipolar disorder, with approximately 50% of patients initiating treatment in this manner and persisting with treatment over the long term.(18) More recent evidence has indicated that the atypical antipsychotics also have antidepressant effects, and treatment guidelines are adapting to reflect the possibility of m…”
BackgroundYatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S. V., MacQueen, G., McIntyre, R. S., Sharma, V., Beaulieu, S., & for CANMAT guidelines group (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00432.x · Cited by 264
Thase, M. E., Jonas, A., Khan, A., Bowden, C. L., Wu, X., McQuade, R. D., Carson, W. H., Marcus, R. N., & Owen, R. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181618eb4 · Cited by 251 · cited 2×
“This consistency of effect is in contrast to that observed with other acute bipolar depression treatment options, including lamotrigine and aripiprazole.(42,43) The differentiating factor for quetiapine may be its mechanism of action, which may involve a combination of direct and indirect effects mediated by quetiapin…”
BackgroundResultCalabrese, J. R., Huffman, R. F., White, R. L., Edwards, S., Thompson, T. R., Ascher, J. A., Monaghan, E. T., & Leadbetter, R. A. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00500.x · Cited by 248 · cited 2×
“This consistency of effect is in contrast to that observed with other acute bipolar depression treatment options, including lamotrigine and aripiprazole.(42,43) The differentiating factor for quetiapine may be its mechanism of action, which may involve a combination of direct and indirect effects mediated by quetiapin…”
BackgroundResultVieta, E., Martinez-Aran, A., Goikolea, J. M., Torrent, C., Colom, F., Benabarre, A., & Reinares, M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0607 · Cited by 227 · cited 1×
“instability with paroxetine is thought to be significantly lower than that associated with the tricyclic antidepressants(29) and venlafaxine.(17,48) In the current study, the incidence of treatment-emergent mania or hypomania observed with both doses of quetiapine was lower than that reported with placebo and paroxeti…”
ResultYoung, L. T., Joffe, R. T., Robb, J. C., MacQueen, G. M., Marriott, M., & Patelis-Siotis, I. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.124 · Cited by 211
Screening for Bipolar Disorder in a Primary Care Practice
Das, A. K. (2005) · JAMA · doi:10.1001/jama.293.8.956 · Cited by 203
Suicide in Bipolar Disorder: Risks and Management
Baldessarini, R. J., Pompili, M., & Tondo, L. (2006) · CNS Spectrums · doi:10.1017/s1092852900014681 · Cited by 183
Treatment guidelines for bipolar disorder: A critical review
Fountoulakis, K. N., Vieta, E., Sanchez-Moreno, J., Kaprinis, S. G., Goikolea, J. M., & Kaprinis, G. S. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.01.004 · Cited by 177
Diagnosis and management of patients with bipolar II disorder.
Yatham, L. N. (2005) · PubMed · Cited by 163
Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression
Schatzberg, A. F., & Kraemer, H. C. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00846-5 · Cited by 106 · cited 1×
“with some studies reporting placebo response rates as high as 70%.(46) Additionally, we cannot discount the impact of in-”
BackgroundMaggino, F. (2023) · Springer eBooks · doi:10.1007/978-3-031-17299-1_302531 · Cited by 99
Bipolar Depression in a Low-Income Primary Care Clinic
Olfson, M., Das, A. K., Gameroff, M. J., Pilowsky, D., Feder, A., Gross, R., Lantigua, R., Shea, S., & Weissman, M. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.2146 · Cited by 66
Bauer, M., Zaninelli, R., Muller-Oerlinghausen, B., & Meister, W. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199904000-00012 · Cited by 42
Bipolar II Disorder: Current and Future Treatment Options
El‐Mallakh, R. S., Weisler, R. H., Townsend, M. H., & Ginsberg, L. D. (2006) · Annals of Clinical Psychiatry · doi:10.1080/10401230600948480 · Cited by 18 · cited 1×
“The atypical antipsychotic quetiapine was the first agent to be licensed as monotherapy to treat depression associated with bipolar I and II disorder.(22) The FDA indication for quetiapine was granted on the basis of the pivotal BOLDER I and II (BipOLar DEpRession) trials.”
BackgroundSelf-citation
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Self-citationYatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
“The eight-week acute-phase results of the EMBOLDEN I (90) and II (91) trials have also been published but the long-term data remain available only in abstract form.”
BackgroundMethodInfluentialKatzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Geddes, J. R., & Miklowitz, D. J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60857-0 · Cited by 848
Metadata
- Authors
- McElroy, S. L., Weisler, R. H., Chang, W., Olausson, B., Paulsson, B., Brecher, M., Agambaram, V., Merideth, C., Nordenhem, A., Young, A. H., & EMBOLDEN II (Trial D1447C00134) Investigators
- Affiliations
- Lindner Center of HOPE (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-01-26
- Volume
- 71
- Issue
- 02
- Pages
- 163-174
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2091962144
- Cited by
- 328
- References
- 47
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 13 · 2023: 12 · 2022: 12 · 2021: 12 · 2020: 11 · 2019: 13 · 2018: 24 · 2017: 17 · 2016: 19 · 2015: 25 · 2014: 30 · 2013: 28 · 2012: 37
- FWCI
- 26.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- quetiapine, paroxetine, bipolar depression, bipolar disorder, major depressive episode, monotherapy, atypical antipsychotics, antidepressants, treatment-emergent mania, hypomania, adverse events, drug tolerability, dose comparison, anxiety symptoms, sedation, xerostomia, insomnia, nausea, headache, dizziness, sleepiness
- MeSH terms
- Quetiapine Fumarate, Adolescent, Adult, Aged, Antidepressive Agents, Bipolar Disorder, Dibenzothiazepines, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Psychiatric Status Rating Scales, Severity of Illness Index, Treatment Outcome, Paroxetine, Antidepressive Agents, Second-Generation, Antimanic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.